Industry

The 25-week weight loss study which achieved its previously reported primary endpoints also examined the effects of GS200 on insulin resistance BOSTON–(BUSINESS WIRE)–Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released a poster presentation at the International Congress of Endocrinology in Singapore. The LIGHT-UP study evaluated … [Read more…]

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended June 30, 2022. Corporate and Clinical Development Highlights Include: Strong Balance Sheet – On June 30, 2022, Can-Fite … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Inhalable Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information about the Inhalable Drug Delivery pipeline products with comparative analysis of the products at various stages of development and information about … [Read more…]

Vaccine efficacy of 85.7% was observed in participants with more severe disease primary endpoint of lower respiratory tract illness (LRTI-RSV) defined by analysis of three or more RSV–associated symptoms Investigational vaccine was well-tolerated with no safety concerns Based on the findings of this pre-planned, interim efficacy analysis, Pfizer intends to submit for regulatory approval in … [Read more…]

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca and Merck, known as MSD outside of the United States and Canada, today announced that LYNPARZA has been approved by the Japan Pharmaceuticals and … [Read more…]

Data presentations to cover findings relevant to the long-term safety and efficacy profile for Adtralza® (tralokinumab) in the treatment of moderate-to-severe atopic dermatitis1,2,3   Studies on delgocitinib and clinical and patient-reported outcomes to provide insight into this investigational treatment for chronic hand eczema4,5 BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma A/S, a global leader in medical dermatology, will … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmacovigilance Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global pharmacovigilance market is expected to grow from $5.71 billion in 2021 to $6.64 billion in 2022 at a compound annual growth rate (CAGR) of 16.2%. The pharmacovigilance market is expected to reach $10.57 billion in 2026 at a CAGR … [Read more…]

IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. today announces the Vizient Clinical Data Base® recently welcomed its 1,000th hospital participant, a milestone that marks its place as the definitive analytics platform for hospital performance and financial improvement. Vizient is the largest member-driven healthcare performance improvement company in the U.S. and serves more than half the nation’s healthcare providers. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Precision Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type, Application, and End User” report has been added to ResearchAndMarkets.com’s offering. The global precision diagnostics market is expected to grow from US$ 79,776.88 million in 2022. to US$ 1,68,405.71 million by 2028. Factors such as the increasing demand for … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Community Oncology Services Global Market Report 2022, By Type, By Cancer Type, By Therapy Type” report has been added to ResearchAndMarkets.com’s offering. The global community oncology services market is expected to grow from $70.06 billion in 2021 to $70.56 billion in 2022 at a compound annual growth rate (CAGR) of 0.7%. The slow … [Read more…]